<DOC>
	<DOCNO>NCT00644358</DOCNO>
	<brief_summary>This open label 52-week clinical trial design assess safety tolerability vilazodone analyze genetic marker response vilazodone adult patient diagnose MDD . This study enroll approximately 600 patient .</brief_summary>
	<brief_title>A One Year Open Label Study Assessing Safety Tolerability Vilazodone Patients With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description>Patients enrol approximately 40 US investigative site receive vilazodone 52 week open label treatment . Safety measurement include adverse event , vital sign , laboratory , ophthalmologic exam , Changes Sexual Function Questionnaire ( CSFQ ) scale ECG finding collect course treatment period . Effectiveness measurement do baseline visit week 52 end-of-treatment . A DNA sample collect genetic analysis relate response vilazodone .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Males female 1870 year age . Meets DSMIVTR criterion Major Depressive Disorder . HAMD score â‰¥ 18 first 17 item 21item HAMD Screening Baseline Visits . Patients must general ocular health . Patients history schizophrenia , schizoaffective disorder bipolar I II disorder ( history hypomanic manic episode ) . Patients meet DSMIVTR criterion substance abuse dependence within 1 year Baseline visit . Patients , Investigator 's judgment , pose serious suicidal homicidal risk make suicide attempt within 6 month prior Screening Visit . Patients take psychotropic drug . Patients take psychotropic drug must discontinue prior Screening Visit . Patients take migraine medication serotonergic mechanism action . Patients take CYP3A4 inhibitor grapefruit juice , ketoconazole , diltiazem , macrolide antibiotic . Patients know hypersensitivity SSRIs 5HT1a agonist . Patients previously treat vilazodone . Patients take Chantix St. John 's Wort . Presence significant acute chronic medical disorder history physical exam . Patients history seizure disorder . Prior history malignancy patient &lt; 5 yr survival OR complete treatment &lt; 1yr prior enrollment currently without evidence recurrence . Skin cancer malignant melanoma permit . Patients evidence central nervous system disorder include psychosis , delirium , dementia amnesic disorder . Patients renal impairment hepatic impairment . Patients euthyroid . Patients serious medical neurological disorder condition make unlikely patient could complete one year treatment would otherwise preclude administration study medication . Female patient must pregnant , lactate , plan become pregnant time study participation . All female patient least 1 year post menopausal irreversibly surgically sterilize must use adequate reliable contraception throughout trial . Patients clinically significant ECG abnormality , determine investigator , make unlikely patient would complete one year treatment would otherwise preclude treatment vilazodone . Patients clinically significant abnormal laboratory finding . Patients positive drug screen . Patients , opinion investigator , would noncompliant visit schedule study procedure . Patients take investigational drug participate investigational drug trial within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>